The results of a blind trial of Sorafenib were promising. Patients on Sorafenib lives nearly 20% longer than patients on the placebo.
"You are not curing the disease but you are delaying the progression of the disease significantly and strikingly," said Llovet, of Mount Sinai School of Medicine in New York and Hospital Clinic of Barcelona, Spain.
The results were released Monday at the American Society of Clinical Oncology's annual meeting.Read Full Story
Sorafenib is a new drug that is being tested on liver cancer patients, with initially promising results. Sorafenib is marketed as Nexavar.